Chemistry:Otenabant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H25Cl2N7O |
| Molar mass | 510.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ↑ "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist". Tetrahedron 64 (48): 10802–10809. 2008. doi:10.1016/j.tet.2008.09.057.
- ↑ "The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction". Journal of the American Academy of Physician Assistants Suppl Endocannabinoid (11): 7–10. November 2007. doi:10.1097/01720610-200711000-00005. PMID 18047036.
- ↑ "Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies". https://www.pfizer.com/news/press-release/pfizer-press-releases?rssUrl=http%3A//mediaroom.pfizer.com/portal/site/pfizer/index.jsp%3FndmViewId%3Dnews_view&ndmConfigId=1010794&newsId=20081105006339&newsLang=en.
 |  |
